Meilleure Health Intrntnl Indu : VOLUNTARY ANNOUNCEMENT BUSINESS UPDATES

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED

美 瑞 健 康 國 際 產 業 集 團 有 限 公 司

(Incorporated in Bermuda with limited liability)

(Stock Code: 2327)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATES

This is a voluntary announcement made by Meilleure Health International Industry Group Limited (the "Company", together with its subsidiaries, the "Group") to inform its shareholders of the latest business developments of an associate of the Group, Yunnan Hansu Biotechnology Co., Ltd. （雲南漢 素生物科技有限公司）("Yunnan Hansu").

On 8 October 2019, the Company was notified by Yunnan Hansu that there is progress in the share transfer and capital increase of Yunnan Hanmeng Pharmaceutical Co., Ltd.（雲 南 漢 盟 製 藥 有 限 公 司 ） ("Hanmeng"), a company of which Yunnan Hansu is the single largest shareholder; the evaluation result in respect of these transaction has been filed to the actual controller of the share transferee and subscriber of capital increase for record. The share transferee and subscriber of capital increase (the "Transferee of the Equity Interest") is an A-share listed company. The filed evaluation result is the consistent with the pervious related evaluation report issued by third party.

Before that, on 8 April 2019, the Transferee of Equity Interest announced that it intends to acquire 37.14% equity interest in Hanmeng held by Yunnan Hansu, through its wholly-owned subsidiary, at a consideration of RMB200 million, and it also intends to increase the share capital of Hanmeng by not more than RMB138 million. Yunnan Hansu invested RMB16 million in Hanmeng, so it will record a considerable gain from this transaction. As of the date of this announcement, Yunnan Hansu has received a deposit of RMB70 million from the Transferee of Equity Interest and will receive the remaining transfer consideration of RMB130 million. After completing the transaction, Yunnan Hansu will not hold any equity interest in Hanmeng. The Group holds 25.55% equity interest in Yunnan Hansu. In addition, it is the second largest shareholder of Yunnan Hansu and it has a board seat in Yunnan Hansu.

To the best of the knowledge of the directors of the Company, being one of the world's first-tier and leading Chinese manufacturers of cannabinoid extraction and downstream applications, Yunnan Hansu is constantly striving to promote the application and output of advanced extraction solutions; On 22 July 2019, the business scope of Yunnan Hansu was extended and the "transfer of biotechnology" was added in it. The good progress in equity transfer and capital increase of Hanmeng proves that Yunnan Hansu's extraction program has been recognized by the market. We believe that the new business scope will further promote Yunnan Hansu to enhance its business model, increase its sources of revenue, and improve its operating profitability.

- 1 -

By Order of the Board

Meilleure Health International Industry Group Limited

Zhou Wen Chuan

Chief Executive Officer

Hong Kong, 9 October 2019

As at the date of this announcement, the Board comprises Mr. Zhou Xuzhou, Dr. Zeng Wentao and Ms. Zhou Wen Chuan as executive Directors, Dr. Mao Zhenhua as non-executive Director and Mr. Gao Guanjiang, Professor Chau Chi Wai, Wilton and Mr. Wu Peng as independent non-executive Directors.

- 2 -